Analysts await CorMedix Inc (NASDAQ:CRMD) to report earnings on Mar, 15 for the fiscal quarter ending Dec 2015.

They expect $-0.16 EPS, down 43.75% or $0.07 from last year’s $-0.09 per share.

At the moment 1 analyst is watching CorMedix Inc (NASDAQ:CRMD), 0 rate it “Buy”, 0 “Outperform”, 1 “Underperform”, 0 “Sell”, while 0 “Hold”.

The biggest institutional shareholders in CorMedix Inc include BlackRock Advisors LLC which owns 2 million shares in the company valued at $2.74 million. Elliott Management Corp is the second biggest holder with 2 million shares currently valued at 3.95 million whilst Vanguard Group Inc has 1 million shares valued at 2.83 million.

Total shares held by institutions as of the most recent company filings are 8,983,416 with a reported 1,349,012 bought and 530,915 sold. These holdings make up 30.96% of the company’s outstanding shares.

Currently insiders hold 1,133,546 shares in the business which makes up 3.20% of shares. The biggest holder currently is Dr. Gary A. Gelbfish, M.D. who owns 687,927 shares (1.94% of those outstanding), whilst Steven W. Lefkowitz holds 147,399 (0.42% of shares outstanding) and Cora M. Tellez holds 88,386 (0.25% of shares outstanding).

The stock decreased 2.41% or $0.06 during the last trading session, hitting $2.89. CorMedix Inc (NASDAQ:CRMD) has risen 2.08% over the past 6 months and is uptrending.